EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Lucy Lee, Amy-Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Lucy Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: PTC Therapeutics, Inc., Warren, NJ, USA. Hauptthemen laut MEDLINE: Food-Drug Interactions, Huntingtin Protein, Dietary Fats. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of 21 days between the two periods. Twenty‐six participants completed the study. There were minimal changes in the bioavailability and pharmacokinetics of votoplam following administration of a single dose of 20 mg votoplam when taken with low‐fat and high‐fat meals relative to fasted condition. The mean C max , AUC 0–last , and AUC 0–inf for votoplam following administration of a single dose of 20 mg votoplam were 1.4‐fold, 1.2‐fold, and 1.1‐fold higher, respectively, in high‐fat fed conditions, and were 1.3‐fold, 1.1‐fold, and 1.1‐fold higher, respectively, in the low‐fat fed conditions, when compared to fasted conditions. There were no relevant safety findings in any of the treatment groups. Votoplam can be administered with or without food in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Food-Drug InteractionsHuntingtin ProteinDietary FatsHumansMaleAdultCross-Over StudiesBiological AvailabilityFemaleYoung AdultMiddle AgedArea Under CurveDiet, High-FatAdministration, OralFastingHealthy VolunteersMealsDiet, Fat-RestrictedRNA Splicing

Stichwörter der Autor:innen

Huntington's diseasefood effectpharmacokineticsrare disease

Substanzen

Huntingtin ProteinHTT protein, humanDietary Fats

Autor:innen und Institutionen

  • PTC Therapeutics, Inc., Warren, NJ, USA.

Zitieren

APA

Lee, L., Richards, A. L., Reddy, N., Beers, B., Golden, L., & Kong, R. (2025). Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1626

Vancouver

Lee L, Richards AL, Reddy N, Beers B, Golden L, Kong R. Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1626

BibTeX
@article{Lee2025,
  author = {Lee, Lucy and Richards, Amy-Lee and Reddy, Nageswara and Beers, Brian and Golden, Lee and Kong, Ronald},
  title = {Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1626}
}
Kostenlos starten →